title: A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy.
abstract: BACKGROUND
  Poly-2-methoxyethylacrylate (PMEA) is a new coating material, and several studies have revealed that PMEA-coated cardiopulmonary bypass (CPB) circuits have good biocompatibility. This study sought to compare this biocompatibility with those of heparin-coated and noncoated circuits.
  
  
  METHODS
  Forty-five patients undergoing coronary artery bypass grafting were randomly assigned to PMEA-coated (group P, n = 15), heparin-coated (group H, n = 15), or noncoated (group N, n = 15) circuit groups. Clinical data and the following markers were analyzed: (1) platelet preservation by number of platelets; (2) complement (C) activation by C3a and C4a levels; (3) inflammatory response by interleukin-6 (IL-6) and interleukin-8 (IL-8) levels.
  
  
  RESULTS
  Platelet numbers were significantly preserved in group P compared with groups N and H. Postoperative blood loss did not differ among the groups. During CPB, C3a values were significantly lower in group H (536 +/- 145 ng/mL) than in group P (1,458 +/- 433 ng/mL, p < 0.01) and group N (1,815 +/- 845 ng/mL, p < 0.01). The C4a values did not differ 60 minutes after CPB initiation among the groups. The IL-6 and IL-8 levels were significantly lower in group P and group H than in group N.
  
  
  CONCLUSIONS
  The PMEA coating was superior to heparin coating and noncoating in preserving platelets, and was equivalent to heparin coating in terms of the perioperative clinical course and inhibition of inflammatory cytokines, but slightly inferior in reducing complement activation.
authors.affiliation: Department of Cardiovascular Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. nama@msic.med.osaka-cu.ac.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ikuta
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Fujii
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Shibata
authors.forename: Koji
authors.initials: K
authors.lastname: Hattori
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Hirai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kumano
authors.forename: Shigefumi
authors.initials: S
authors.lastname: Suehiro
mesh_terms: D000179:Acrylates / Q000494:pharmacology; D000368:Aged; D000925:Anticoagulants; D002315:Cardiopulmonary Bypass; D020099:Coated Materials, Biocompatible; D015926:Complement C3a / Q000032:analysis; D015934:Complement C4a / Q000032:analysis; D005260:Female; D006493:Heparin; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D008297:Male; D010976:Platelet Count; D011108:Polymers / Q000494:pharmacology
chemical_list: D000179:Acrylates; D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D011108:Polymers; C413485:poly(2-methoxyethylacrylate); D015926:Complement C3a; D015934:Complement C4a; D006493:Heparin